Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gastrointestinal Metabolic Disorders Cardiovascular

Cancer And Rare Diseases Top EU Drug Approvals In 2015

This article was originally published in Scrip

Executive Summary

  • 46 new active substances approved
  • First stem cell therapy
  • First drug for mitochondrial dysfunction
  • 12 new anticancers
  • 16 drugs for rare diseases
  • Five accelerated approvals
  • Four conditional approvals
  • Three exceptional circumstances approvals
  • Second-highest number of CHMP recommendations

    • Table

    View full table

    Topics

    Tags:
    Gastrointestinal Metabolic Disorders Cardiovascular
    Latest Headlines

    Australia Calls For Companion Testing Plans For Drugs Requiring A CDx

    Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

    The Aspirin Test For AI?

    Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

    See All
    UsernamePublicRestriction

    Register

    SC064222

    Ask The Analyst

    Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

    Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

    All fields are required.

    Please make sure all fields are completed.

    Please make sure you have filled out all fields

    Please make sure you have filled out all fields

    Please enter a valid e-mail address

    Please enter a valid Phone Number

    Ask your question to our analysts

    Cancel

    This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

    Printed By